Stella Catharina Maria Heemskerk

Stella Catharina Maria Heemskerk

Auto-generated profile, based on publicly available information

Stella Catharina Maria Heemskerk

Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, Room EE-1589, PO Box 2040, 3000 CA, Rotterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Journal of Affective Disorders
Verified
Journal Article
Closed access
RORobbin H. Ophuis
Robbin H. Ophuis
JLJoran Lokkerbol
Joran Lokkerbol
SHStella C.M. Heemskerk
Stella C.M. Heemskerk
ABAnton J.L.M. van Balkom
Anton J.L.M. van Balkom
MHMickaël Hiligsmann
Mickaël Hiligsmann
SESilvia M.A.A. Evers
Silvia M.A.A. Evers

23 November 2023 in Annals of Surgery
Verified
Journal Article
Open access
SHStella C.M. Msc Heemskerk
Stella C.M. Msc Heemskerk
CDCarmen D. Dirksen
Carmen D. Dirksen
SKSander M.J. van Kuijk
Sander M.J. van Kuijk
MBMarc Alexander Benninga
Marc Alexander Benninga
CBCoen I.M. Baeten
Coen I.M. Baeten
SBStéphanie O. Breukink
Stéphanie O. Breukink
Objective: Assess the effectiveness of sacral neuromodulation (SNM) versus personalized conservative treatment (PCT) in patients with refractory idiopathic slow-transit constipation (STC). Background: Evidence on SNM for idiopathic STC is conflicting and of suboptimal methodological quality. Methods: The No.2-Trial was a multicenter, open-label, pragmatic, randomized trial performed in 2 Dutch hospitals. Sixty-seven patients with idiopathic STC, a defecation frequency <3 per week and refractory (ie, unresponsive) to maximal conservative (nonoperative) treatment were included. Exclusion criteria included outlet obstruction, rectal prolapse, and previous colon surgery. Patients were randomized (3:2) to SNM (n=41) or PCT (n=26) with randomization minimization between February 21, 2017 and March 12, 2020. In SNM patients, an implantable pulse generator was implanted after a successful 4-week test stimulation. PCT patients received conservative treatment such as laxatives or retrograde colonic irrigation. The primary outcome was treatment success (defined as average defecation frequency ≥3 per week) after 6 months. Secondary outcomes included constipation severity, fatigue, quality of life, and adverse events. Analysis was according to intention-to-treat. Results: After 6 months, 22 (53.7%) patients were successfully treated with SNM versus 1 (3.8%) patient with PCT (odds ratio 36.4, 95% CI 3.4–387.5, P=0.003). At 6 months, SNM patients reported lower constipation severity and fatigue scores (P<0.001) and improved quality of life compared with PCT (P<0.001). Eight serious adverse events (6 SNM, 2 PCT) and 78 adverse events (68 SNM, 10 PCT) were reported. Conclusions: SNM is a promising surgical treatment option in a homogeneous group of adults and adolescents with refractory idiopathic STC. No.2-Trial registered at ClinicalTrials.gov NCT02961582.

22 August 2019 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
SHStella C M Heemskerk
Stella C M Heemskerk
ARAdriënne H Rotteveel
Adriënne H Rotteveel
JMJarno Melenhorst
Jarno Melenhorst
SBStéphanie O Breukink
Stéphanie O Breukink
MKMerel L Kimman
Merel L Kimman
CDCarmen D Dirksen
Carmen D Dirksen
Background and Aim: Standardizing evaluative outcomes and their assessment facilitates comparisons between clinical studies and provides a basis for comparing direct effects of different treatment options. The aim of this study was to systematically review types of outcomes and measurement instruments used in studies regarding treatment options for slow‐transit constipation (STC) in adults.Methods: In this systematic review of the literature, we searched MEDLINE, Embase, and PsycINFO from inception through February 2018, for papers assessing any STC treatment in adult patients. Outcomes were systematically extracted and categorized in domains using the conceptual framework of the Outcome Measures in Rheumatology filter 2.0. Outcome reporting was stratified by decade of publication, intervention, and study type.Results: Forty‐seven studies were included in this systematic review. Fifty‐nine different types of outcomes were identified. The outcomes were structured in three core areas and 18 domains. The most commonly reported domains were defecation functions (94%), gastrointestinal transit (53%), and health‐care service use (51%). The most frequently reported outcomes were defecation frequency (83%), health‐related quality of life (43%), and adverse events and complications (43%). In 62% of the studies, no primary outcome was defined, whereas in two studies, more than one primary outcomes were selected. A wide diversity of measurement instruments was used to assess the reported outcomes.Conclusion: Outcomes reported in studies on STC in adults are heterogeneous. A lack of standardization complicates comparisons between studies. Developing a core outcome set for STC in adults could contribute to standardization of outcome reporting in (future) studies.

21 January 2024 in Colorectal Disease
Verified
Journal Article
Open access
SHStella C. M. Heemskerk
Stella C. M. Heemskerk
AWAart A. van der Wilt
Aart A. van der Wilt
BPBart M. F. Penninx
Bart M. F. Penninx
JKJos Kleijnen
Jos Kleijnen
JMJarno Melenhorst
Jarno Melenhorst
SBStéphanie O. Breukink
Stéphanie O. Breukink
Aim: Sacral neuromodulation (SNM) is a minimally invasive treatment option for functional constipation. Evidence regarding its effectiveness is contradictory, driven by heterogeneous study populations and designs. The aim of this study was to assess the effectiveness, safety and cost‐effectiveness of SNM in children and adults with refractory idiopathic slow‐transit constipation (STC). Method: OVID Medline, OVID Embase, Cochrane Library, the KSR Evidence Database, the NHS Economic Evaluation Database and the International HTA Database were searched up to 25 May 2023. For effectiveness outcomes, randomized controlled trials (RCTs) were selected. For safety outcomes, all study designs were selected. For cost‐effectiveness outcomes, trial‐ and model‐based economic evaluations were selected for review. Study selection, risk of bias and quality assessment, and data extraction were independently performed by two reviewers. For the intervention ‘sacral neuromodulation’ effectiveness outcomes included defaecation frequency and constipation severity. Safety and cost‐effectiveness outcomes were, respectively, adverse events and incremental cost‐effectiveness ratios. Results: Of 1390 records reviewed, 67 studies were selected for full‐text screening. For effectiveness, one cross‐over and one parallel‐group RCT was included, showing contradictory results. Eleven studies on safety were included (four RCTs, three prospective cohort studies and four retrospective cohort studies). Overall infection rates varied between 0% and 22%, whereas reoperation rates varied between 0% and 29%. One trial‐based economic evaluation was included, which concluded that SNM was not cost‐effective compared with personalized conservative treatment at a time horizon of 6 months. The review findings are limited by the small number of available studies and the heterogeneity in terms of study populations, definitions of refractory idiopathic STC and study designs. Conclusion: Evidence for the (cost‐)effectiveness of SNM in children and adults with refractory idiopathic STC is inconclusive. Reoperation rates of up to 29% were reported.

29 November 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
CGChahinda Ghossein-Doha
Chahinda Ghossein-Doha
MWMarieke S J N Wintjens
Marieke S J N Wintjens
EJEmma B N J Janssen
Emma B N J Janssen
DKDorthe Odyl Klein
Dorthe Odyl Klein
SHStella C M Heemskerk
Stella C M Heemskerk
SKSander M J van Kuijk
Sander M J van Kuijk
Introduction The variety, time patterns and long-term prognosis of persistent COVID-19 symptoms (long COVID-19) in patients who suffered from mild to severe acute COVID-19 are incompletely understood. Cohort studies will be combined to describe the prevalence of long COVID-19 symptoms, and to explore the pathophysiological mechanisms and impact on health-related quality of life. A prediction model for long COVID-19 will be developed and internally validated to guide care in future patients. Methods and analysis Data from seven COVID-19 cohorts will be aggregated in the longitudinal multiple cohort CORona Follow Up (CORFU) study. CORFU includes Dutch patients who suffered from COVID-19 at home, were hospitalised without or with intensive care unit treatment, needed inpatient or outpatient rehabilitation and controls who did not suffer from COVID-19. Individual cohort study designs were aligned and follow-up has been synchronised. Cohort participants will be followed up for a maximum of 24 months after acute infection. Next to the clinical characteristics measured in individual cohorts, the CORFU questionnaire on long COVID-19 outcomes and determinants will be administered digitally at 3, 6, 12, 18 and 24 months after the infection. The primary outcome is the prevalence of long COVID-19 symptoms up to 2 years after acute infection. Secondary outcomes are health-related quality of life (eg, EQ-5D), physical functioning, and the prevalence of thromboembolic complications, respiratory complications, cardiovascular diseases and endothelial dysfunction. A prediction model and a patient platform prototype will be developed. Ethics and dissemination Approval was obtained from the medical research ethics committee of Maastricht University Medical Center+ and Maastricht University (METC 2021-2990) and local committees of the participating cohorts. The project is supported by ZonMW and EuroQol Research Foundation. Results will be published in open access peer-reviewed scientific journals and presented at (inter)national conferences. Trial registration number NCT05240742.

22 February 2018 in International Journal of Colorectal Disease
Verified
Journal Article
Open access
PDF file
SHS. C. M. Heemskerk
S. C. M. Heemskerk
ARA. H. Rotteveel
A. H. Rotteveel
MBM. A. Benninga
M. A. Benninga
CBC. I. M. Baeten
C. I. M. Baeten
AMA. A. M. Masclee
A. A. M. Masclee
SBS. O. Breukink
S. O. Breukink
Purpose The evidence regarding the (cost-)effectiveness of sacral neuromodulation (SNM) in patients with therapy-resistant idiopathic slow-transit constipation is of suboptimal quality. The Dutch Ministry of Health, Welfare and Sports has granted conditional reimbursement for SNM treatment. The objective is to assess the effectiveness, cost-effectiveness, and budget impact of SNM compared to personalized conservative treatment (PCT) in patients with idiopathic slow-transit constipation refractory to conservative treatment. Methods This study is an open-label, multicenter randomized controlled trial. Patients aged 14 to 80 with slow-transit constipation, a defecation frequency (DF) < 3 per week and meeting at least one other Rome-IV criterion, are eligible. Patients with obstructed outlet, irritable bowel syndrome, bowel pathology, or rectal prolapse are excluded. Patients are randomized to SNM or PCT. The primary outcome is success at 6 months (DF ≥ 3 a week), requiring a sample size of 64 (α = 0.05, β = 0.80, 30% difference in success). Secondary outcomes are straining, sense of incomplete evacuation, constipation severity, fatigue, constipation specific and generic quality of life, and costs at 6 months. Long-term costs and effectiveness will be estimated by a decision analytic model. The time frame is 57 months, starting October 2016. SNM treatment costs are funded by the Dutch conditional reimbursement program, research costs by Medtronic. Conclusions The results of this trial will be used to make a final decision regarding reimbursement of SNM from the Dutch Health Care Package in this patient group. Trial registration This trial is registered at clinicaltrials.gov, identifier NCT02961582, on 12 October 2016.